



# **Effect of Central Dialysis Fluid Delivery System (CDDS) on IL6 & CRP Levels in Prevalent Haemodialysis Patients**

Thesis

*Submitted for Partial Fulfillment of Master Degree  
in Internal Medicine*

By

**Ahmed Elsayed Elsayed Mohamed Moustafa**

*M.B.B.Ch.*

*Misr University for Science and Technology*

Under Supervision of

**Prof. Dr/ Hesham Mohamed Elsayed**

*Professor of Internal Medicine and Nephrology*

*Faculty of Medicine, Ain Shams University*

**Prof. Dr/ Badawy Labeed Mahmoud**

*Professor of Nephrology*

*Faculty of Medicine, Misr University for Science and Technology*

**Dr/ Mohamed Saeed Hassan**

*Lecturer of Internal Medicine and Nephrology*

*Faculty of Medicine, Ain Shams University*

*Faculty of Medicine - Ain Shams University*

2020

بِسْمِ اللَّهِ الرَّحْمَنِ الرَّحِيمِ

# قَالَ

سُبْحَانَكَ لَا عِلْمَ لَنَا  
إِلَّا مَا عَلَّمْتَنَا إِنَّكَ أَنْتَ  
الْعَلِيمُ الْعَظِيمُ

صدق الله العظيم

سورة البقرة الآية: ٣٢

# Acknowledgments

*First and foremost, I feel always indebted to **Allah** the Most Beneficent and Merciful.*

*I wish to express my deepest thanks, gratitude and appreciation to **Prof. Dr/ Hesham Mohamed Elsayed**, Professor of Internal Medicine and Nephrology, Faculty of Medicine, Ain Shams University, for his meticulous supervision, kind guidance, valuable instructions and generous help.*

*Special thanks are due to **Prof. Dr/ Badawy Labeab Mahmoud**, Professor of Nephrology, Faculty of Medicine, Misr University for Science and Technology, for his sincere efforts, fruitful encouragement.*

*I am deeply thankful to **Dr/ Mohamed Saeed Hassan**, Lecturer of Internal Medicine and Nephrology, Faculty of Medicine, Ain Shams University, for his great help, outstanding support, active participation and guidance.*

*I would like to express my hearty thanks to all my family for their support till this work was completed.*

**Ahmed Elsayed Elsayed Mohamed Moustafa**

# List of Contents

Title	Page No.
List of Tables.....	5
List of Figures .....	6
List of Abbreviations.....	8
Introduction .....	- 1 -
Aim of the Work .....	14
Review of Literature	
▪ Inflammation in Chronic Kidney Disease .....	15
▪ IL-6 & CRP in Hemodialysis.....	30
▪ Central Dialysis Fluid Delivery Systems .....	43
Patients and Methods .....	57
Results.....	59
Discussion .....	74
Summary.....	83
Conclusion .....	85
References .....	86
Arabic Summary	

# List of Tables

Table No.	Title	Page No.
<b>Table 1:</b>	Interpretation of serum CRP and atherosclerotic cardiovascular disease.....	40
<b>Table 2:</b>	Microbiological Quality Standard for Dialysis Fluids in Japan, excerpt from reference:.....	50
<b>Table 3:</b>	Standard on the management of endotoxin retentivefilter (ETRF), excerpt from reference.....	54
<b>Table 4:</b>	Demographic characteristics regarding group 1 (CDDS) and group 2(SPDS): .....	59
<b>Table 5:</b>	Comparison between group 1 (CDDS) and group 2 (SPDS) regarding laboratory data: .....	60
<b>Table 6:</b>	IL-6 and CRP in group 1 (CDDS) and 2 (SPDS): .....	61
<b>Table 7:</b>	Correlation between IL-6 and different variables in group 1 (CDDS): .....	63
<b>Table 8:</b>	Correlation of hs CRP with different variables in group 1 (CDDS): .....	64
<b>Table 9:</b>	Correlation between IL-6 and different variables in group 2 (SPDS): .....	65
<b>Table 10:</b>	Correlation of hs CRP with different variables in group 2 (SPDS): .....	66
<b>Table 11:</b>	Multivariate analysis to explore predictors of IL-6 within CDDS group .....	67
<b>Table 12:</b>	Multivariate analysis to explore predictors of hs CRP within CDDS group .....	70
<b>Table 13:</b>	Multivariate analysis to explore predictors of IL-6 within SPDS group .....	71
<b>Table 14:</b>	Multivariate analysis to explore predictors of hs CRP within SPDS group.....	73

# List of Figures

Fig. No.	Title	Page No.
<b>Figure 1:</b>	Causes and consequences of inflammation in CKD .....	19
<b>Figure 2:</b>	Showing differences between thin low-flux (left) and porous high-flux membranes (right) regarding permeation and adsorption of bacterial products, complement activation and removal of pro-inflammatory substances. ....	27
<b>Figure 3:</b>	IL-6 Structure.....	30
<b>Figure 4:</b>	Interleukin-6 and mechanisms for receptor signalling. ....	33
<b>Figure 5:</b>	CRP Structure .....	37
<b>Figure 6:</b>	Scheme of the single-patient dialysis fluid delivery system (SPDDS), central concentrates delivery systems (CCDS), and central dialysis fluid delivery system (CDDS).....	46
<b>Figure 7:</b>	Outline of the newly development of CDDS.....	55
<b>Figure 8:</b>	Describes the processes used by the CDDS to achieve dialysis fluid purification in a flow chart. ....	56
<b>Figure 9:</b>	Shows fully automated dialysis system (FADS) (a) Automated guiding of blood into the dialyzer. (b) Blood return and collection. Red lines indicate the flow of blood, and blue lines indicate the flow of the dialysate. ....	56
<b>Figure 10:</b>	Comparison between hsCRP in group 1(CDDS) and group 2(SPDS). ....	62
<b>Figure 11:</b>	Comparison between IL6 in group 1(CDDS) and group 2(SPDS). ....	62

# List of Figures cont...

Fig. No.	Title	Page No.
<b>Figure 12:</b>	Association between IL6 and hs CRP in group 1(CDDS). .....	68
<b>Figure 13:</b>	Comparison between IL6 and Dry weight in group 1(CDDS). .....	68
<b>Figure 14:</b>	Comparison between IL6 and Albumin in group 1(CDDS). .....	69
<b>Figure 15:</b>	Comparison between IL6 and hs CRP in group 2(SPDS). .....	72

# List of Abbreviations

Abb.	Full term
AAMI .....	<i>Advancement of Medical Instrumentation</i>
AGEs .....	<i>Advanced glycosylated end-products</i>
AMP .....	<i>Adenosine MonoPhosphate</i>
BCM .....	<i>Biocompatible membrane</i>
CCDS .....	<i>Central concentrates delivery systems</i>
CDDS.....	<i>Central Dialysis Fluid Delivery System</i>
CFUs .....	<i>Colony-forming units</i>
CKD .....	<i>Chronic kidney disease</i>
CRP .....	<i>Serum reactive protein</i>
CVD .....	<i>Cardiovascular disease</i>
ESRD .....	<i>End-stage Renal disease</i>
ET.....	<i>Endotoxin</i>
ETRFs .....	<i>Eendotoxin retentive filters</i>
FADS .....	<i>Fully Automated Dialysis System</i>
GFR .....	<i>Glomerular filtration rate</i>
gp130.....	<i>Glycoprotein 130</i>
HD .....	<i>Hemodialysis</i>
HDF .....	<i>Hemodiafiltration</i>
HPA .....	<i>Hypothalamic-pituitary-adrenal axis</i>
IFEHD .....	<i>Internal Filtration-Enhanced Dialysis</i>
IL-1 .....	<i>Interleukin-1</i>
IL-6.....	<i>Interleukin-6</i>
IL-6R .....	<i>Iinterleukin-6 receptor</i>
Jak .....	<i>Janus kinase</i>
JSDT .....	<i>Japanese Society for Dialysis Therapy</i>
LRVs .....	<i>Logarithmic reduction values</i>
MCO .....	<i>Medium cut-off</i>
NHANES .....	<i>National Health and Nutrition Examination Survey III</i>
OS .....	<i>Oxidative stress</i>
PD .....	<i>Peritoneal dialysis</i>
PDGF .....	<i>Platelet derived growth factor</i>
PEW .....	<i>Protein-energy wasting</i>



# List of Abbreviations cont...

Abb.	Full term
<i>pg / mL</i>	<i>Picogram per millilitre</i>
<i>PTFE</i>	<i>Polytetrafluoroethylene</i>
<i>RAK</i>	<i>Rapidly Accelerated Fibrosarcoma</i>
<i>RAS</i>	<i>Rapidly Accelerated Sarcoma</i>
<i>RO</i>	<i>Reverse Osmosis</i>
<i>SOCS</i>	<i>Suppressor of cytokine signalling proteins</i>
<i>SPDDS</i>	<i>Single patient dialysis fluid delivery system</i>
<i>STAT</i>	<i>Signal transducer and activator of transcription</i>
<i>TNFalpha</i>	<i>Tumor necrosis factor alpha</i>
<i>Tyk2</i>	<i>Tyrosine Kinase</i>
<i>µg / mL</i>	<i>Microgram per millilitre</i>

# INTRODUCTION

**E**nd-stage kidney disease (ESKD) is a significant and growing public health problem, associated with high morbidity, mortality and diminished quality of life. ESKD also generates disproportionately high costs to the health care system as patients require renal replacement therapy, for long-term survival (*Li et al., 2018*).

Incidence of ESRD is increasing worldwide at an annual growth rate of 8%, far more than the population growth rate which is of 1.3%. Only about 15% of those with ESRD are receiving hemodialysis worldwide, with about 80% being treated in Europe, North America, and Japan (*Sanyaolu et al., 2018*).

In the 2015 Global Burden of Disease Study, kidney disease was the 12th most common cause of death, accounting for 1.1 million deaths worldwide. Overall CKD mortality has increased by 31.7% over the last 10 years, making it one of the fastest rising major causes of death (*Neu et al., 2017*).

Millions die each year because they do not have access to affordable treatment, Over 2.5 million people worldwide currently receive treatment, yet this number may only represent 10% of people who actually need treatment to live (*Couser et al., 2015*).

Despite recent advances in end-stage renal disease (ESRD) management, morbidity and mortality in this population remain exceptionally high. Dialysis is considered as a chronic inflammatory state, as there is increased production and decreased clearance of pro-inflammatory cytokines, oxidative stress and acidosis, chronic and recurrent infections, including those related to dialysis access where extracorporeal factors, such as impurities in dialysis water, microbiological quality of the dialysate, and bioincompatible factors in the dialysis circuit play an additional role (*Akchurin & Kaskel, 2015*).

In patients with renal failure, the systemic concentrations of both pro-inflammatory and anti-inflammatory cytokines are several times higher than that in healthy individuals. HD results in activation of cytokines, which can induce protein catabolism and promote apoptosis. In HD patients, inflammatory mediators, such as IL-1, IL-6, and tumor necrosis factor alpha, cause synthesis and release of C-reactive protein (CRP), decreased albumin, prealbumin, and increased homocysteine and endothelin I (*Raj et al., 2007*).

IL-6 increases during HD and is associated with cardiovascular mortality, malnutrition, and resistance to erythropoietin (EPO) in haemodialysis patients. It is considered a prognostic marker in these patients (*Hasuike et al., 2009*).

In hemodialysis, more than 90% of the dialysate delivered to the dialyzer is water, so water purity for dialysis is of critical importance for patient health and outcome, as hemodialysis patients are exposed to more than 400 L of water per week. Contrast this with a person with normal kidney drinking only less than 15 L of water per week and this purification depends on water treatment systems which decrease water contamination (*Ahmad, 2005*).

Water contamination can lead to anemia, alterations in blood pressure and acid-base balance, neurological issues, bone disease, increased levels of inflammatory indices on long run and more, and patients may suffer acute or chronic problems from exposure to substandard dialysate (*D'Amato-Palumbo et al., 2013*).

Currently available dialysis fluid delivery systems include the single-patient dialysis fluid delivery system (SPDDS) (or individual dialysis fluid delivery system) and central concentrates delivery systems (CCDS), as well as the CDDS (central dialysis fluid delivery systems) (*Hideki et al., 2016*).

In SPDDS, the patient monitor contains a dialysis fluid supply equipment. Presently, it is considered as the global standard for dialysis treatment. Many of its models require separate water treatment equipment. Aside from the advantage of the relatively free location, SPDDS allows for the

individualization of dialysis fluid composition in order to meet unique patient needs (*Hideki et al., 2016*).

The central dialysis fluid delivery system (CDDS) simplifies the maintenance and supervision involved by enabling the combined management of dialysis fluid for multiple persons, preparation of cleaning and antiseptic solutions, and delivery of these to each patient monitor. It is a cost-effective, laborsaving, time-tested system with good microbial safety, which has been used for 45 years. Reliability is required in CDDS systems, as a single abnormality can affect multiple patients negatively (*Hideki et al., 2016*).

The CDDS has been used exclusively in Japan since 1960s. Approximately 88 % of dialysis machines are patient monitors with CDDS. It is widely known that the survival rate of Japanese hemodialysis patients is the highest in the world. This is mainly due to the development of dialysis and blood purification devices and development of the dialysis system. The introduction of the central dialysis fluid delivery system (CDDS) in the 1960s enabled the provision of stable dialysis conditions for all patients, which made a marked contribution to the field of dialysis (*Takahashi et al., 2016*).

## **AIM OF THE WORK**

**I**t is to compare the effect of central dialysis fluid delivery system (CDDS) versus single-patient dialysis fluid delivery system (SPDDS) in purification of water that used in dialysate, and its effect on inflammatory markers (CRP & IL-6) levels in prevalent hemodialysis patients.

## Chapter 1

# INFLAMMATION IN CHRONIC KIDNEY DISEASE

End-stage kidney disease (ESKD) is a significant and growing public health problem, associated with high morbidity, mortality and diminished quality of life. ESKD also generates disproportionately high costs to the health care system as patients require renal replacement therapy, for long-term survival (*Li et al., 2018*).

Incidence of ESRD is increasing worldwide at an annual growth rate of 8%, far more than the population growth rate which is of 1.3%. Only about 15% of those with ESRD are receiving hemodialysis worldwide, with about 80% being treated in Europe, North America, and Japan (*Sanyaolu et al., 2018*).

In the 2015 Global Burden of Disease Study, kidney disease was the 12th most common cause of death, accounting for 1.1 million deaths worldwide. Overall CKD mortality has increased by 31.7% over the last 10 years, making it one of the fastest rising major causes of death (*Neu et al., 2017*).

Millions die each year because they do not have access to affordable treatment, Over 2.5 million people worldwide currently receive treatment, yet this number may only represent